Capstone Therapeutics Corporation has entered into a significant stock purchase agreement with an accredited investor, involving the potential sale of up to $20 million in common stock. Under the terms of this agreement, Capstone has the option to sell shares to the investor, priced at 97% of the lowest daily volume-weighted average price over a three-day period. Additionally, a recent amendment to this agreement has increased the limits on the volume and dollar amount of shares that can be purchased in a single transaction. This amendment allows for a maximum purchase of up to 40% of the trading volume or $3 million, whichever is lower, enhancing Capstone's financial flexibility and capital-raising options.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.